Magnetic Resonance Tomography, MRI, is one of the most used instruments for non-invasive clinical diagnostics. In contrast to radiological investigations, MRI has no danger of radiation exposure to produce images using radio... [ view full abstract ]
Magnetic Resonance Tomography, MRI, is one of the most used instruments for non-invasive clinical diagnostics. In contrast to radiological investigations, MRI has no danger of radiation exposure to produce images using radio frequency electromagnetic radiation with very low energy. The most researches in this area are focused on the development of contrast agents, that can provide a clearer distinction between healthy and diseased tissue. The majority of contrast agents are magnetic nanoparticles (MNP) [1]. MNPs made from iron oxide are used for the diagnostics of many diseases such as cardiovascular, neurological and cancer. Liver and prostate cancer are the most prevalent of malignant tumors. Hybrid contrast agents are among most popular trends for MRI providing comprehensive data on disease progression. Gadolinium chelates and magnetite are the most appropriate T1 and T2 contrast agents, respectively, but these compounds can provide toxic effect on healthy cells. One of the ways to prevent toxicity is the creation of hybrid contrast agents based on gadolinium doped magnetite [2], [3]. In this work gadolinium doped magnetite nanoparticles were prepared by thermal decomposition of iron-gadolinium complex in dibenzyl ether and Gd(III) acetate and Fe(acac)3 in dibenzyl ether in addition oleic acid, oleylamine and 1,2-hexadecandiol. These nanoparticles are designed to be used as a hybrid contrast agents for hepatocellular and prostate carcinomas visualization. Obtained nanoparticles were investigated by methods of transmission electron microscopy, X-ray diffraction, Mössbauer spectroscopy, dynamic light scattering, zeta potential and thermogravimetric analysis. Also the toxicity of nanoparticles and their T1 and T2-relaxation time were measured in vitro.
The authors knowledge financial support from Ministry of Education and Science of the Russian Federation (№ К2-2016-069).
[1] Z.R. Stephen, MaterialsToday 14, 330 (2011)
[2] C. R. De Silva, J. AM. CHEM. SOC. 131, 6336 (2009)
[3] F.J. Douglas, RSC Adv. 6, 74500 (2016)
Nanomedicine for cancer diagnosis & therapy , Nano-Imaging for diagnosis, therapy and delivery
